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Abstract
Background: There is a clear need for vaccines and therapeutics for potential biological weapons
of mass destruction and emerging diseases. Anthrax, caused by the bacterium Bacillus anthracis, has
been used as both a biological warfare agent and bioterrorist weapon previously. Although
antibiotic therapy is effective in the early stages of anthrax infection, it does not have any effect
once exposed individuals become symptomatic due to B. anthracis exotoxin accumulation. The
bipartite exotoxins are the major contributing factors to the morbidity and mortality observed in
acute anthrax infections.
Methods: Using recombinant B. anthracis protective antigen (PA83), covalently coupled to a novel
non-toxic muramyl dipeptide (NT-MDP) derivative we hyper-immunized goats three times over
the course of 14 weeks. Goats were plasmapheresed and the IgG fraction (not affinity purified) and
F(ab')2 derivatives were characterized in vitro and in vivo for protection against lethal toxin mediated
intoxication.
Results: Anti-PA83 IgG conferred 100% protection at 7.5 μg in a cell toxin neutralization assay.
Mice exposed to 5 LD50 of Bacillus anthracis Ames spores by intranares inoculation demonstrated
60% survival 14 d post-infection when administered a single bolus dose (32 mg/kg body weight) of
anti-PA83 IgG at 24 h post spore challenge. Anti-PA83 F(ab')2  fragments retained similar
neutralization and protection levels both in vitro and in vivo.
Conclusion: The protection afforded by these GMP-grade caprine immunotherapeutics post-
exposure in the pilot murine model suggests they could be used effectively to treat post-exposure,
symptomatic human anthrax patients following a bioterrorism event. These results also indicate
that recombinant PA83 coupled to NT-MDP is a potent inducer of neutralizing antibodies and
suggest it would be a promising vaccine candidate for anthrax. The ease of production, ease of
covalent attachment, and immunostimulatory activity of the NT-MDP indicate it would be a
superior adjuvant to alum or other traditional adjuvants in vaccine formulations.
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Background
Bacillus anthracis, the causative agent of anthrax, has been
the focus of much research and attention following the
release of spores through the US mail system in 2001. 22
cases of infection resulted in 5 deaths, causing much con-
cern regarding treatment, therapeutics and vaccine effi-
cacy. Recently, the CDC discontinued the administration
of the current anthrax vaccine (Anthrax Vaccine Adsorbed
-AVA) due to adverse side effects observed in a large per-
centage of volunteers. This revocation of available vaccine
has left healthcare workers, laboratory personnel and first
responders with only limited means of protection follow-
ing potential exposures to anthrax spores.
In humans, the anthracis bacilli can cause three types of
infections: cutaneous via abrasions in the skin, gastroin-
testinal through ingestion of spores in contaminated meat
and inhalation when spores less than 5 uM um are depos-
ited into the lungs [1]. The mortality rates vary between
each form of the disease with cutaneous anthrax present-
ing as a self-limiting and treatable infection with only a
20% case fatality rate. When left untreated gastrointestinal
infections can progress rapidly and have over 80% case
fatality rates. Inhalation anthrax infections are rare but
have a high case fatality rate (over 75%) even with antibi-
otic treatment.
Treatment options for patients presenting with symptoms
of inhalational anthrax infections are limited and are gen-
erally ineffective at reducing mortality. Although antibi-
otic therapy is effective in the early stages of infection, it
does not have any effect on the bipartite exotoxins, which
are the major contributing factors to the mortality
observed in acute anthrax infections [1]. The current lack
of an approved, available vaccine puts laboratory workers,
military personnel and first responders at an increased
risk of inhalational anthrax should another terrorist event,
similar to the anthrax mailings in 2001, occur. Clearly
there is a need for an effective vaccine as well as a well-tol-
erated, economical, post-exposure therapeutic for the
treatment of human anthrax infections.
Passive immunotherapy is a non-chemical therapeutic
providing immediate immunity to infectious agents and
toxins. This treatment option has been shown to be effec-
tive against many diseases including anthrax [2-6] and
other biothreat agents [7,8]. Several approaches have been
used previously for the production of immunotherapeu-
tics specific for B. anthracis although they all have signifi-
cant drawbacks. The pooling of immune serum from
previously vaccinated volunteers yields highly protective
anti-sera in very small quantities, limiting its use as a
source of therapeutics for the Strategic National Stockpile
or as a commercially available product. Monoclonal anti-
bodies are highly specific, limiting their application to a
single antigenic target and have a high cost associated
with their development further limiting their feasibility
for mass production and stockpiling. In the past animal
vaccination has successfully been used to generate immu-
notherapeutic antiserum specific for infectious and toxic
agents including snake venom, botulism toxin and Ebola
virus [9-12] but limitations in quantity and safety have
prevented their widespread use in the development of
human therapeutics. Horses can provide large amounts of
antiserum but are costly to maintain. Mice, rabbits and
guinea pigs are inexpensive to maintain but yield limited
volumes of anti-sera. Goats provide a renewable source of
plasma and serum; however they have not been tradition-
ally used in the generation of passive immunotherapeu-
tics. We have plasmapheresed hyper immunized goats to
successfully produce liters of GMP-grade antisera follow-
ing a short immunization schedule (3 immunizations
over 14 weeks), with minimal cost.
Bacillus anthracis produces two separate exotoxins, edema
toxin (EdTx) and lethal toxin (LeTx). The two exotoxins
utilize a common cell binding component termed protec-
tive antigen (PA83, 83 kDa) which binds to the ubiqui-
tous anthrax toxin receptor (ATR) found on most cell
surfaces. Once PA83 is bound to the host cell surface, a
furin-like protease cleaves the full-length, inactive protein
into the active form, PA63 (63 kDa), thereby exposing the
binding sites for the catalytic components of the exotoxins
(edema factor, EF or lethal factor, LF). A heptamer com-
posed of PA63 + three LF/EF moieties [13,14] forms on
the cell surface and is internalized via receptor mediated
endocytosis. The subsequent decrease in pH within the
endosome causes conformational changes in PA63, so
that it inserts into the endosomal membrane, forming a
protease-stable pore; formation of this pore allows EF and
LF to enter the cell and exert their toxic effects [15]. LeTx
is formed when PA63 is combined with LF, and is respon-
sible for the most severe intoxicative effects of anthrax
infection. EF is an adenylate cyclase capable of causing
severe disregulation of cellular cAMP levels [16]. LF has
been shown to be a zinc-dependant metalloprotease with
specificity for mitogen-activated protein kinase kinases
(MAPKKs) capable of disrupting several cell signaling cas-
cades; however, its specific mode of action is still unclear
[17,18]. Disruption of the binding of PA to ATR or LF
would disrupt internalization of functional LeTx and
would thereby prevent toxin-mediated death of the host
following rapid multiplication of the bacilli.
Here we immunized goats with recombinant PA83, cou-
pled to a novel non-toxic muramyl dipeptide derivative
(NT-MDP) capable of inducing both innate and humoral
immunity and does not induce clotting even when
administered at high concentrations. The resulting poly-
clonal anti-sera conferred protection against in vitro and inJournal of Immune Based Therapies and Vaccines 2007, 5:11 http://www.jibtherapies.com/content/5/1/11
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vivo intoxication with the anthrax lethal toxin (LeTx) and
in vivo intranasal challenge with virulent B. anthracis
spores. Recently, we have shown that the passive transfer
of goat-derived anti-HIV antibodies to failing therapy
AIDS patients has been well tolerate, safe and effective
[19-21].
In order to circumvent any hypersensitivity reactions asso-
ciated with goat IgG, we have explored the use of F(ab')2
antibodies lacking the Fc region of the IgG molecule. The
Fc region of the IgG is involved in the activation of com-
plement, and patients with a pre-developed sensitivity to
goat proteins may be at a higher risk of developing fatal
allergic reactions following the administration of a goat-
based antibody therapy. Removal of the Fc region allows
for the retention of the dimeric antigen binding sites
while increasing the safety of the immunotherapeutic
without a significant loss in neutralizing capabilities.
Our data suggests that the administration of anti-PA83
goat IgG or F(ab')2 would provide an efficacious and well-
tolerated passive immunotherapy for post-exposure treat-
ment of acute human anthrax infections. Most notable is
the rapidity with which the anti-sera were produced in
goats and the volume of anti-sera generated from a single
plasmapheresis. In addition, this data serves a proof of
concept that a rapid, inexpensive, GMP-grade immuno-
therapeutic can be produced in a short enough timeframe
for an emerging disease event like SARS-CoV.
Methods
Recombinant anthrax toxin proteins
High-purity, histidine-tagged rLF and rPA83 were sup-
plied by the Northeast Biodefense Center Protein Expres-
sion Core. Functional lethal toxin (LeTx) was formed by
the combination of purified rLF and rPA83 at a 1:1 (w/w)
ratio diluted in sterile PBS.
Caprine antisera
Purified rPA83 was supplied to Virionyx Corporation Ltd
(Auckland, NZ) for caprine immunizations as follows. A
novel muramyl dipeptide adjuvant (NT-MDP) was oxi-
dized with sodium meta periodate (0.5 M) for 1 h and
excess sodium meta periodate was removed by centrifuga-
tion followed by a water wash. 1 mg of rPA83 in sodium
carbonate buffer (0.1 M, pH 9.5) was added to 10 mg of
activated NT-MDP and incubated overnight at room tem-
perature. The resulting Schiff's base was reduced by the
addition of ascorbic acid to achieve a pH of 7.0. Three
goats were immunized with 100 μg rPA83-NT-MDP con-
jugates emulsified in Freund's complete adjuvant and
were subsequently boosted three additional times with
immunogen in Freund's incomplete adjuvant over a 13-
week period. Hyper-immune plasma was collected from
each animal two weeks following the last immunization.
Plasma was pooled and IgG was purified using a standard
octanoic acid precipitation technique. Purified anti-PA83
IgG was supplied at a concentration of 15 mg/ml.
Generation of F(ab')2 antibody fragments
F(ab')2  fragments were generated by pepsin digestion
(100 U/mg IgG) at pH 3.5 in 0.1 M glycine buffer for 24
h. Reactivity was demonstrated using an Ouchterlony gel
diffusion assay and demonstrated reactivity at 1 mg/ml
against rabbit anti-goat IgG (data not shown). Purity and
extent of digestion was determined by SDS-PAGE analysis
(data not shown).
Anti-sera titer determination
ELISAs were performed in microtiter plates coated with
rPA83 (10 nM) in 10 mM carbonate/bicarbonate buffer
(pH 8.5) with a final coating volume of 50 μl. Plates were
coated for 1 h then washed in water and blocked with 5%
non-fat milk powder. Antibody titers were measured by
reacting (2 h) serially diluted anti-PA83 IgG with the
rPA83-coated microtiter wells. The wells were then
washed with water and reacted (2 h) with horseradish per-
oxidase-labeled rabbit anti-goat IgG. Following one water
wash, the wells were reacted (30 min) with the substrate,
orthophenylenediamine. The reaction was stopped by the
addition of sulfuric acid and absorbance was measured at
492 nm. Anti-PA83 IgG titers were measured and
expressed as the reciprocal of the antibody dilution which
produced an absorbance value equal to 50% maximum
absorbance.
Cell lines and media
Murine macrophage-like cells, J774A.1, were obtained
from the American Type Cell Culture Collection (ATCC
TIB-67). Cells were cultured in complete medium: Dul-
becco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum, Glutamax, and penicillin/
streptomycin at 37°C with 5% CO2.
In vitro cytotoxicity and protection assays
Macrophage-like cells were harvested by gentle scraping
(no trypsin) and were seeded in 96-well plates at a density
of 6 × 104 cells/well in 100 μl of complete medium. Cells
were incubated for 18–24 h or until > 90% confluency
had been achieved. Medium was removed, and cells were
washed once in sterile PBS before addition of toxin or
anti-sera. For toxicity assays, 100 μl of LeTx was added to
the cells at final concentrations of 1000 ng, 100 ng, 10 ng
and 0.1 ng (data not shown). For protection assays, 50 ng
of LeTx (2 TCEC50) was combined with varying dilutions
of anti-PA83 IgG or F(ab')2 and incubated at 37°C, while
shaking for 1 h prior to the addition of 100 μl per well.
Cells with LeTx alone or in combination with anti-sera
were incubated at 37°C and 5% CO2 for 4 h. Cell viability
was determined using Sigma's Cell Growth Determina-Journal of Immune Based Therapies and Vaccines 2007, 5:11 http://www.jibtherapies.com/content/5/1/11
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tion Kit, an MTT-based assay. Briefly, 10 μl of MTT dye was
added to cells and incubated for 15 h at 37°C and 5%
CO2. 100 μl of solubilization solution was added to each
well after removal of media, and cell viability was meas-
ured at 570 nm. Percent relative cell viability was calcu-
lated as the ratio between LeTx-treated cells (LeTx) and
untreated control cells (100 μl PBS). Percent protection
conferred by caprine anti-PA83 IgG or F(ab')2 was meas-
ured as follows:
(1-((PBS - α PA83 IgG)/(PBS - 50 ng LeTx))) × 100.
In vivo protection assays
Lethal toxin challenge
Female Balb/c mice (average weight 17.5 g) were injected
with 100 μg LeTx in 200 μl saline via intraperitoneal injec-
tion (5 per group). Five minutes following toxin injection
mice were injected on the opposite side with 8 mg/kg anti-
PA83 IgG or F(ab')2 in 200 μl saline. Control mice (3 in
group) received LeTx followed by saline injections. Mice
were observed for signs of illness and distress for 11 days
at which point all surviving mice were sacrificed.
Virulent B. anthracis spore intranasal challenge
Female Swiss Webster mice (average weight 25.2 g) were
infected with approximately 5 × 104 B. anthracis Ames
spores (5 LD50) by 20 μl installations in each nares.
Groups of 10 mice received saline at 1 hour post-infection
or anti-PA83 IgG at 24 h post-infection (32 mg/kg) by
intraperitoneal injection. Mice were monitored twice
daily for 14 d for signs of illness and death. To evaluate
synergistic effects of antibiotic treatment post-exposure,
low-dose Ciprofloxacin was administered twice daily at
0.9 mg/day via intraperitoneal injection for the first six
days post spore challenge.
Statistical Analysis of in vivo results
Statistical analysis (logrank test) of the in vivo survival data
was performed using GraphPad Prism (version 4.03),
GraphPad Software, San Diego, CA.
Results and Discussion
Anthrax lethal toxin activity
Purified rLF (90 kDa) and rPA83 (83 kDa) showed high
product purity, with no significant breakdown products by
SDS PAGE, trypsin digestion and mass spectroscopy (>
95% purity for both, data not shown). In vitro bioactivity of
LeTx was confirmed by treating J774A.1 murine macro-
phage-like cells with varying doses of LeTx (10 – 0.001 ng/
μl), and cell viability determined via toxin neutralization
assay. Cell viability experiments established a TCEC50 of 25
ng LeTx (equivalent to 2.85 nM, data not shown). This dose
of LeTx is within the range of previously reported TCEC50s
[22-25]. Based on this data, all subsequent in vitro protec-
tion assays were performed at 2× TCEC50 equivalent to a
total of 50 ng LeTx per well.
Generation and evaluation of anti-PA83 caprine 
immunoglobulin
One goal of this study was to produce large volumes of high
titer, hyper-immune goat sera in a short period of time.
Goats were immunized four times (days 0, 14, 28, 56) over
a period of 56 days and subsequently plasmapheresed (day
94). Total IgG was purified from plasma and rPA83 specif-
icity was confirmed by Western blot and ELISA (data not
shown), validating the efficacy of the immunogen/adju-
vant, immunization schedule, and IgG purification meth-
ods established previously with the anti-HIV
immunotherapeutic [19-21]. Specific rPA83 titers were
obtained from immunized goats on days 0, 27, 40, 54, 67,
and 94. Antibody titers were measured by ELISA by reacting
serially diluted anti-PA83 IgG with 10 nM rPA83. Anti-
PA83 IgG demonstrated significant titer (> 10,000, calcu-
lated as the reciprocal of the dilution producing 50% max-
imum absorbance) within 2 weeks (27 d post-
immunization), and reached a maximum of ~16,000 after
the fourth immunization (Fig. 1). High titer polyclonal
antisera could be generated in as little as 42 days thus estab-
lishing that rapid production of target-specific caprine
Goat anti-PA83 IgG titer Figure 1
Goat anti-PA83 IgG titer. Serially diluted goat anti-PA83 IgG 
reacted with 10 nM rPA83 in a microplate ELISA. Titer calcu-
lated as the reciprocal of the dilution producing 50% maxi-
mum absorbance. Day 0 is 1st immunization with PA83-NT-
MDP, asterisks indicate timings of 2nd (day 14), 3rd (day 28) 
and 4th (day 56) booster immunizations. Purified anti-PA83 
IgG was obtained from plasmapheresed goats on day 94 
(time point designated by a square).
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immunotherapeutics using the novel NT-MDP adjuvant is
achievable.
Anti-PA83 IgG and F(ab')2 protect cells against LeTx-
induced cytotoxicity
The protective efficacy of the anti-PA83 IgG and the F(ab')2
derivative was evaluated in the J774A.1 LeTx in vitro model.
Cells were exposed to 0.5 ng/μl of LeTx and dilutions of
anti-PA83 IgG or F(ab')2. MTT-based cell viability assays
were used to determine percent protection as described in
Materials and Methods. Control included untreated cells
(i.e., PBS substituted for LeTx), cells treated with IgG alone
(7.5 μg α PA83 Ig with no LeTx), or cells treated with 0.5
ng/μl LeTx alone (LeTx). LeTx treated cells demonstrated a
statistically significant decrease in cell viability (p < 0.001)
as compared to the untreated PBS control cells, while stand-
ard concentrations of anti-PA83 IgG (7.5 μg) had no effect
on cell viability (data not shown). The use of higher con-
centrations of anti-PA83 IgG (up to 250 μg) produced no
significant differences in cell viability (data not shown).
These results confirm that caprine IgG exhibits no inherent
cytotoxic effects in vitro and does not interfere with the
observed cytotoxicity of the recombinant LeTx.
Cells treated with varying concentrations of anti-PA83 IgG
exhibited protection from LeTx cytotoxicity in a dose-
dependant manner (Fig. 2A). Cells were exposed (five sep-
arate assays each with four replicates) to varying doses of
anti-PA83 IgG and 50 ng LeTx for 4 h. 7.5 μg anti-PA83 IgG
fully protected cells against LeTx mediated cell death, while
0.95 μg offered minimal protection (35%) over the LeTx
treated control cells (Fig. 2A). Treatment of LeTx exposed
cells with anti-PA83 F(ab')2 demonstrated equivalent pro-
tection at 7.5 μg compared to anti-PA83 IgG (Fig. 2B). At
lower doses, there was an observable diminished protec-
tion afforded by the anti-PA83 F(ab')2 compared to whole
IgG. These data confirm that rapidly produced caprine
immunotherapeutics, either whole IgG or despeciated
F(ab')2 fragments, elicit complete protection against LeTx-
mediated cytotoxicity in vitro.
In vivo protection of mice following LeTx challenge
Efficacy for the anti-PA83 IgG and F(ab')2 immunothera-
peutics was established in an intraperitoneal LeTx-chal-
lenge mouse model (Fig. 3). The LeTx -challenge mouse
model simulates a post-exposure, symptomatic patient.
Mice were first injected with 2LD100  (200  μg LeTx) of
recombinant LeTx on the left side of the abdomen. This
dose of LeTx has been confirmed to be fatal to 100% of
mice within 48 h post challenge (data not shown). After
five minutes, mice were injected with approximately 8 mg/
kg anti-PA83 IgG or F(ab')2 immunotherapeutics on the
right side of the abdomen. Control mice received 200 μl of
PBS instead of IgG or F(ab')2. Control mice succumbed to
LeTx by day 2 while IgG and F(ab')2 treated groups showed
80% and 100% survival, respectively. F(ab')2-treated group
survival rates declined to 80% on day 3 and remained there
throughout the 11 d study. The IgG-treated group also
showed 80% protection for the remainder of the study. The
ability for the goat derived passive immunotherapeutic to
protect against an in vivo LeTx challenge suggests its poten-
tial for use as a therapeutic intervention in humans. Since
this model simulates a symptomatic patient, we speculated
that the anti-PA83 immunotherapeutics could be used effi-
caciously post-exposure to prevent mortality.
In vitro protection against LeTx cytotoxicity Figure 2
In vitro protection against LeTx cytotoxicity. J774A.1 cells 
were treated with 50 ng (~2.9 nM) LeTx and varying concen-
trations of goat anti-sera. Cell viability determined by an 
MTT-based assay. A. Anti-PA83 IgG. Data shown are the 
average ± SEM of five assays each with four replicates. EC50 is 
2.57 × 10-7 M. B. Anti-PA83 F(ab')2 fragment. Data shown are 
the average ± SEM of three assays each with four replicates. 
EC50 is 4.0 × 10-7 M, comparable to full length IgG. Curves 
and EC50 were generated using GraphPad Prism® V4.03.
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Passive protection of mice 24 hours post-infection with 
Ames spores
To evaluate post-exposure efficacy of the anti-PA83 IgG, a
mouse model of inhalational anthrax was used. Female
Swiss Webster mice were challenged with virulent B. anthra-
cis spores via an intranasal infection route. Mice received 5
LD50 B. anthracis Ames spores in 20 μl instillations into
each nares. Control mice received saline at 1 h post-chal-
lenge. Twenty-four hours post-challenge, test groups
received 32 mg/kg caprine anti-PA83 IgG by intraperitoneal
injection. At 4 d post-infection (p.i.), only 20% of control
mice survived, while 70% of mice treated with anti-PA83
IgG were still alive (Fig. 4A). By day 6, another 10% of the
mice in each group had succumbed to disease and no fur-
ther mortality was observed through the remaining 14 d
study. One test group also received low-dose Ciprofloxacin
to examine synergistic effects of post-exposure treatments
(Fig. 4B). Mice treated with antibiotics alone exhibited a
50% survival rate out to the end of the study (14 d p.i.). Sur-
vival of IgG treated mice dropped to 60% by day 6 p.i. and
remained there through the completion of the study. Con-
comitant administration of Ciprofloxacin (twice daily on
days 1–6) and anti-PA83 IgG (single bolus at 24 h p.i.)
completely protected mice for 6 days (Fig. 4B) while Cipro-
floxacin was administered. When Ciprofloxacin treatment
was stopped, survival decreased to levels comparable to
anti-PA83 IgG treatment alone. These results confirm the
potential for passive transfer of immunity up to 24 hours
post exposure to B. anthracis spores and suggest parallel
treatment with antibiotics can significantly enhance sur-
vival.
Many groups have shown the efficacy of polyclonal, ani-
mal-derived sera for use as a passive immunotherapeutic
against anthrax infections, however these groups have
relied on smaller animal models (e.g., mice, rabbits,
guinea pigs) to generate the antisera [3,4,26,27]. Smaller
animals are typically terminally bled in order to produce
larger volumes of serum. Yields from a terminal bleed typ-
ically range from 0.5 ml for mice up to 200 ml for termi-
nally bled rabbits. The large number of animals required
to produce the therapeutic quantities needed for a useful
medical countermeasure stockpile (e.g., the SNS) makes
these animal models prohibitively expensive. Caprine
plasmapheresis does not require the animals to be eutha-
nized/terminally bled in order to generate large volumes
of antisera. Additionally, the goats can be plasmapheresed
up to four times per year for several years making for a
nearly endless source of antisera. Plasmapheresis of three
goats generated liters of anti-PA83 serum within a very
short time frame. Additionally, the goats used to produce
this material are part of a certified pathogen-free herd and
the antisera produced are of GMP grade. Comparably pro-
duced IgG against HIV has been previously approved for
clinical trials in humans [19-21].
The previously approved AVA anthrax vaccine required a
series of six immunizations followed by annual boosts. The
use of a novel non-toxic MDP adjuvant enabled the gener-
ation of extremely high-titer antiserum following only two
immunizations although for the current study, IgG was iso-
lated from goats immunized four times. With further opti-
mization of the immunization regiment, we may be able to
generate an efficacious immunotherapeutic with fewer
immunizations, thus shortening the production time and
cost. It should also be emphasized that the data presented
here used non-affinity-purified IgG or F(ab')2. Studies are
underway to evaluate the efficacy of the affinity purified
materials, which may significantly reduce the amount of
material required to offer significant protection in both ani-
mals and humans.
F(ab')2 antibodies have been used for the treatment of rat-
tlesnake bites [28,29], bee stings [30] and evaluated for
their potential to treat several infectious diseases including
respiratory syncitial virus (RSV) [31]. Many monoclonal
antibodies (MAbs) have been generated that are specific for
the anthrax protective antigen. The majority of these MAbs
do not demonstrate significant protection post-exposure
and appear to require a blend of several MAbs in order to
reduce the mortality associated with anthrax infections
[32,33]. A recent study using a monoclonal antibody
against the anthrax protective antigen demonstrated a
requirement for the Fc portion of the antibody in order to
retain neutralizing capabilities [25]. Our polyclonal immu-
notherapeutic retained similar neutralizing levels both in
vitro and in vivo after removal of the Fc region by pepsin
In vivo protection against LeTx cytotoxicity Figure 3
In vivo protection against LeTx cytotoxicity. Percent survival 
of female Balb/c mice treated with 100 μg LeTx by i.p. injec-
tion followed 5 minutes later with 8 mg/kg anti-PA83 IgG or 
F(ab')2 antibodies in 200 μl (5 per group). Control mice 
(Saline, 3 in group) received 100 μg LeTx followed by 200 μl 
Saline. All mice were observed twice daily for signs of illness 
or distress and all surviving mice were euthanized at day 11 
post-challenge. P < 0.03 by the logrank test.
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digestion. These findings are consistent with data from
other polyclonal antiserum, which indicate most F(ab')2
retain comparable neutralizing and protective abilities to
full length IgG [26,29,30,34]. The utility of F(ab')2 antisera
derived from goats will reduce the potential for side-effects
associated with patients who have a pre-existing sensitivity
to goat proteins. In addition, patients requiring multiple
treatments with an animal derived therapeutic may also be
at increased risk of developing allergic hypersensitivity, so
the use of F(ab')2 antibody fragments will decrease this risk
and increase the overall safety of this immunotherapeutic
for multiple uses within a large population.
Conclusion
This work has shown that pharmaceutical-grade goat poly-
clonal immunotherapeutics specific for the anthrax protec-
tive antigen can be rapidly produced in large quantities.
Three goats immunized four times over a 56 day period
produced liters of GMP grade, high titer antisera that was
capable of neutralizing anthrax lethal toxin both in vitro
and in vivo. More importantly the passive transfer of the
goat-derived antibodies 24 h post-exposure to virulent
anthrax spores provided mice with a substantial survival
advantage over untreated mice. A synergistic effect was seen
with concomitant antibiotic treatment although levels of
protection returned to the levels observed with IgG treat-
ment alone once antibiotic therapy was discontinued. This
indicates that a combined treatment approach for patients
presenting with clinical signs of anthrax infection could
overall increase in survival rates associated with sympto-
matic disease. Additionally, this immunotherapeutic can
be easily produced in quantities large enough to fulfill the
requirements for a national medical countermeasures
stockpile. The non-toxic MDP adjuvant developed is easily
produced; amenable to covalent attachment of antigens,
and importantly, renders toxins and pathogens inactive
once coupled to the molecule. The use of this novel adju-
vant should improve vaccine development and quality con-
trol in addition to eliciting significantly higher immune
responses than standard adjuvants.
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In vivo protection against intranasal virulent anthrax challenge Figure 4
In vivo protection against intranasal virulent anthrax challenge. Percent survival of female Swiss Webster mice, 10 per group, 
infected with 5 LD50 B. anthracis Ames spores by intranasal inoculation. Control mice were treated with saline 1 h post spore 
challenge via intraperitoneal injection. All mice were monitored twice dailyfor signs of illness or death. A. Mice were treated 
with 32 mg/kg anti-PA83 IgG 24 h post spore challenge via intraperitoneal injection. P = 0.0161 by thelogrank test. B. Mice 
were treated with Ciprofloxacin alone or in combination with anti-PA83 IgG at 32 mg/kg (24 h post spore challenge). Cipro-
floxacin was administered twice daily at 0.9 mg/day via intraperitonealinjection for the first six days post spore challenge. Statis-
tical significance using the logrank test as follows: Anti-PA83 IgG P = 0.0161, Anti-PA83 IgG + Ciprofloaxcin P = 0.0007 and 
Ciprofloaxcin P = 0.0156.
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